- Home
- MYNZ vs HSCS Comparison
MYNZ vs HSCS Comparison
Compare MYNZ & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | HSCS |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 9.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYNZ | HSCS |
|---|---|---|
| Price | $0.61 | $2.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $9.20 |
| AVG Volume (30 Days) | ★ 385.4K | 17.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,072.41 |
| Revenue Next Year | $5.03 | $2,700.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $2.01 |
| 52 Week High | $5.69 | $6.47 |
Technical Indicators
Market Signals| Indicator | MYNZ | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 25.41 | 45.69 |
| Support Level | $0.56 | $2.72 |
| Resistance Level | $1.37 | $3.08 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 7.54 | 46.43 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.